- Nuformix is eligible to receive an up front, development milestone along with royalties when the net sales reaching $2.76M/annum
- Oxilio gets an exclusive license to research, develop and commercialize NXP001 globally for oncology indications. The agreement allows Oxilio to focus on developing a unique formulation and dosage form with NXP001 to progress into the clinic
- NXP001 is a new form of aprepitant which is marketed in the oncology supportive care setting. Additionally, Nuformix has obtained the patents on new forms of NXP001 with improved properties & focuses to develop two lead assets NXP002 and NXP004
Click here to read full press release/ article | Ref: Nuformix | Image: Linkedin
The post Nuformix Signs an Exclusive WW License Agreement with Oxilio to Develop NXP001 for Oncology Disease first appeared on PharmaShots.